Vancouver, British Columbia--(Newsfile Corp. - May 7, 2026) - The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) (the "Company" or "BPC"), a publicly traded wellness company focused on advanced peptide formulations and delivery systems, today provides an update on the development of its needle-free BPC-157 transdermal patch - a product designed to give consumers a frictionless route into the peptide category for the first time.

The BPC-157 patch is currently in active testing, with results anticipated in the near term. Subject to the satisfactory completion of these testing milestones, the Company intends to progress the product closer to commercial release as part of The Precision Peptide Company's product portfolio.

For decades, the peptide category has been gated by the needle. While interest in peptides has grown rapidly across recovery, longevity, and broader wellness, the majority of consumers have never crossed the threshold into the category - research consistently identifies needle aversion as a leading barrier to therapies that consumers would otherwise consider. Adoption has therefore skewed toward biohackers, athletes, and clinical populations already comfortable with self-administered injectables.

The innovative patch is designed to remove that barrier entirely. Worn directly on the skin and precision-engineered for controlled, sustained peptide delivery, the patch eliminates the reconstitution, sterile handling, and dose measurement associated with injectable peptide therapies. The result is a wearable, mainstream-ready format intended to bring BPC-157 and other formulas to consumers who have followed the rise of peptides from a distance and have been waiting for a delivery format they would actually use.

Pratap Sandhu, CEO of The Precision Peptide Company, commented:

"This is the product that brings peptides into the mainstream. The needle has historically been the single biggest barrier to entry for this category, and removing it fundamentally changes who the customer is. The patch is built for the person who has read the headlines, listened to the podcasts, and decided peptides aren't for them because they aren't willing to inject. We believe it is the bridge between where peptides have come from and the far larger consumer market they can serve, and the progression of testing to date supports our confidence in that path."

Justin Kirkland, Chief Scientific Officer of Amino Innovations, added:

"BPC-157 has decades of preclinical research behind it, and translating that molecule from an injectable into a transdermal format is a meaningful piece of formulation work. The patch is engineered to deliver consistently through the skin in a way that performs reliably outside of an injection setting. The data we are generating through this testing programme is what gives us confidence in the patch as a credible, scalable alternative to traditional peptide administration - and, in our view, a real step forward for how the category reaches everyday consumers."

The BPC-157 patch is the first product to advance from the Company's broader transdermal patch pipeline. A second patch - the Company's Immune Defense Patch, formulated with Thymosin Alpha-1 (TA-1) and developed on the same delivery platform - is also under development, and is expected to follow BPC-157 through testing and toward commercial readiness in due course. Together, the two products are intended to establish the foundation of a multi-product needle-free peptide platform under the Amino Innovations brand.

Patch development is supported by the Company's previously announced research services agreement with the Drug Development and Innovation Centre (DDIC) at the University of Alberta, where Dr. Neal Davies and Dr. Raimar Loebenberg, senior professors in the Faculty of Pharmacy and Pharmaceutical Sciences, provide scientific expertise across absorption, bioavailability, and stability work relevant to the Company's peptide portfolio.

The BPC-157 patch will sit alongside the Company's existing oral peptide product line, manufactured in an approved U.S. facility and distributed across North America through the Amino Innovations brand.

There is no assurance that the testing currently underway will produce results that satisfy the Company's internal benchmarks, that the BPC-157 patch or the Immune Defense Patch will be commercialised on the timelines currently contemplated, or that any subsequent product launch will result in revenue or other benefit to the Company. The Company will provide further updates as material developments occur.

About The Precision Peptide Company

The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) is a publicly traded wellness company building a next-generation platform for high-quality peptide formulations. By combining scientific formulation and innovative delivery technologies, the Company creates products at the intersection of biotechnology and scalable consumer wellness. Products are manufactured in an approved U.S. facility and distributed across North America.

For more information, visit: www.precisionpeptidecompany.com

Cautionary Note Regarding Forward-Looking Information

This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. Forward-looking information includes, but is not limited to, statements relating to: the anticipated timing and outcome of testing of the BPC-157 transdermal patch; the Company's intention to progress the BPC-157 patch toward commercial release; the anticipated development and commercialization of the Immune Defense Patch; the establishment of a multi-product needle-free peptide platform under the Amino Innovations brand; and the expected benefits of the Company's research services agreement with the Drug Development and Innovation Centre (DDIC) at the University of Alberta.

Forward-looking information is based on certain key expectations and assumptions made by the Company, including that: testing of the BPC-157 patch will proceed on the timelines currently contemplated and will produce results consistent with the Company's internal benchmarks; no adverse regulatory, scientific, manufacturing, or supply chain developments will materially delay or prevent commercialization of the Company's products; the research services agreement with the DDIC will continue in its current form; and general business and economic conditions will not change in a manner materially adverse to the Company.

Although the Company believes that the expectations and assumptions on which the forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Since forward-looking information addresses future events and conditions, by its very nature it involves inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks, including, but not limited to: the risk that testing of the BPC-157 patch does not produce satisfactory results; the risk that the Company is unable to commercialize the BPC-157 patch or the Immune Defense Patch on the timelines currently contemplated, or at all; the risk that the transdermal delivery of BPC-157 does not achieve adequate bioavailability or consumer acceptance; and the risk that any subsequent product launch does not result in revenue or other benefit to the Company.

The forward-looking information contained in this news release is made as of the date hereof, and the Company undertakes no obligation to update publicly or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/296392